Free Trial

NuCana (NCNA) Competitors

NuCana logo
$5.64 -0.14 (-2.34%)
As of 01:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NCNA vs. BPTH, BON, VINC, SYRS, PBLA, VRPX, SMFL, NKGN, SCPS, and VAXX

Should you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Bio-Path (BPTH), Bon Natural Life (BON), Vincerx Pharma (VINC), Syros Pharmaceuticals (SYRS), Panbela Therapeutics (PBLA), Virpax Pharmaceuticals (VRPX), Smart for Life (SMFL), NKGen Biotech (NKGN), Scopus BioPharma (SCPS), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry.

NuCana vs. Its Competitors

Bio-Path (NASDAQ:BPTH) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Path
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NuCana
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08MN/AN/A
NuCanaN/AN/A-$24.28M-$646.16-0.01

In the previous week, NuCana had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for NuCana and 0 mentions for Bio-Path. NuCana's average media sentiment score of 0.95 beat Bio-Path's score of 0.00 indicating that NuCana is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Path Neutral
NuCana Positive

NuCana's return on equity of -592.28% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
NuCana N/A -592.28%-208.68%

Bio-Path has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Comparatively, NuCana has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

NuCana beats Bio-Path on 8 of the 9 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCNA vs. The Competition

MetricNuCanaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$165K$3.36B$6.03B$10.48B
Dividend YieldN/A2.31%5.73%4.82%
P/E Ratio-0.0122.0685.4727.11
Price / SalesN/A466.79594.15131.81
Price / CashN/A44.9825.7730.18
Price / Book0.0210.3912.506.70
Net Income-$24.28M-$52.47M$3.32B$276.55M
7 Day Performance-21.51%-0.15%-0.22%-0.02%
1 Month Performance42.75%13.41%8.50%7.10%
1 Year Performance-98.57%19.89%75.45%41.82%

NuCana Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCNA
NuCana
1.3669 of 5 stars
$5.65
-2.3%
N/A-98.6%$169KN/A-0.0130
BPTH
Bio-Path
0.8818 of 5 stars
$0.06
-1.6%
N/A-94.0%$564KN/A0.0010Gap Down
BON
Bon Natural Life
0.6855 of 5 stars
$2.07
+0.9%
N/AN/A$351K$23.84M0.00100Gap Up
VINC
Vincerx Pharma
0.5197 of 5 stars
$0.05
-1.9%
$40.00
+78,331.4%
-99.5%$267KN/A0.0060Negative News
Gap Down
SYRS
Syros Pharmaceuticals
3.7956 of 5 stars
$0.01
+4,900.0%
$1.00
+19,900.0%
-99.7%$134K$386K0.00120Gap Up
PBLA
Panbela Therapeutics
0.0894 of 5 stars
$0.01
+0.9%
N/A-96.9%$54KN/A0.006
VRPX
Virpax Pharmaceuticals
0.0523 of 5 stars
$0.02
+90.9%
N/A-99.8%$26KN/A0.007Gap Up
SMFL
Smart for Life
N/A$0.00
-66.7%
N/A-93.7%$14K$11.11M0.00110Gap Down
NKGN
NKGen Biotech
0.1374 of 5 stars
$0.00
+50.0%
N/A-96.4%$13KN/A0.00N/AGap Up
SCPS
Scopus BioPharma
N/A$0.00
flat
N/AN/A$13KN/A0.009
VAXX
Vaxxinity
N/A$0.00
-99.0%
N/A-97.5%$13KN/A0.0090Gap Down

Related Companies and Tools


This page (NASDAQ:NCNA) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners